← The patent line

Fosnetupitant Chloride Hydrochloride; Palonosetron Hydrochloride

Sold as AKYNZEO · given by intravenous

Ten years or more until it comes off patent
10.8 yr
Until anyone may copy it
Protection runs to 2037-06-02
0
Trials running now
1 registered in total
Phase 1
Furthest stage reached
safety and dose-finding only
1
Organisations running trials
lead sponsors on record
01

Who owns it, and until when

Helsinn Healthcare Sa
Approval holder
the only company permitted to sell it today
2037-06
Last patent expires
latest patent filed against this product
none listed
FDA exclusivity ends
a separate protection granted at approval

Whichever date falls later is when other manufacturers may apply to sell copies. Price typically falls steeply within a year of that point, and with it any company's ability to recover the cost of new research on the molecule. That is when it becomes a candidate for the ledger on the first tab.

02

What it is being tested for

Healthy Volunteers
03

Who is paying for the research

Helsinn Healthcare SA
Company
1

Who funds the trials matters after protection lapses. Company-funded work usually stops once exclusivity ends; university, hospital and government-funded work does not, and is the research most likely to continue on this molecule afterwards.

04

The trials themselves

NCT06840769Phase 12023 · 50 people · stopped early
A Clinical Trial to Assess Safety and Pharma

Expiry dates are what the patent holder has filed; litigation, paediatric extensions and settlements routinely move them, so read these as the earliest plausible date rather than a schedule. Not medical advice.

← Back to the patent line